Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
T-cell engagers
Biotech
Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped
The Big Pharma has abandoned the second and final clinical-stage candidate from the Trillium acquisition.
James Waldron
May 5, 2026 9:15am
UCB inks $2B Candid buyout to join Gilead in autoimmune field
May 4, 2026 7:46am
Janux axes solid tumor T-cell engager after poor ph. 1 showing
Apr 28, 2026 4:15am
After 3 acquisitions, Gilead shifts focus to expanded pipeline
Apr 8, 2026 4:00am
ADCs, TCEs among ‘exciting things’ on Boehringer's shopping list
Apr 3, 2026 8:40am
Gilead's $2.2B Ouro buy delivers TCE, new purpose for Galapagos
Mar 24, 2026 3:34am
